David D. Meek - Dec 19, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
Chief Executive Officer, Director
Signature
/s/ Reena R. Desai, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Dec 19, 2022
Transactions value $
-$186,552
Form type
4
Date filed
12/21/2022, 08:20 PM
Previous filing
Jul 11, 2022
Next filing
Jan 19, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $0 +35.4K +103.7% $0.00 69.6K Dec 19, 2022 Direct F1, F2
transaction MRTX Common Stock Sale -$187K -4.62K -6.63% $40.41 65K Dec 21, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Performance Stock Units ("PSUs"). 1/3 of the PSUs have vested on December 19, 2022 (one week after the "Achievement Date" of December 12, 2022). 1/3 of the remaining shares will vest on the one year anniversary of the Achievement Date and the remaining 1/3 will vest on the two year anniversary of the Achievement Date, subject to Mr. Meek's continuous service.
F2 Includes 64 shares acquired under the ESPP Purchase on 5/31/2022 and 41 shares acquired under the ESPP purchase on 11/30/2022.
F3 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the PSUs referenced in Footnote 1.